Affiliation:
1. Rostov State Medical University
2. Rostov State Medical University; International Medical Center "URO-PRO"
3. International Medical Center "URO-PRO"; RIVIERA BIOTECH, LLC
4. International Medical Center "URO-PRO"
Abstract
Introduction. Currently, along with the improvement of the scheme of combined drug therapy with first-line anti-inflammatory drugs, important importance is attached to adjuvant topical methods of treating diseases of the distal colon of various inflammatory genesis.Aim. Evaluate the clinical efficacy of the drug on sodium hyaluronate as an adjuvant topical agent in the complex treatment of patients with diseases of the distal colon.Materials and methods. A comparative analysis of the results of drug treatment of 97 patients with diseases of the distal colon of various inflammatory genesis, which were divided into two groups, was carried out. In 46 (47.4%) patients of the I (control) group, standard drug therapy with basic anti-inflammatory drugs was performed; 51 (52.6%) patients – II (main) group, the standard program of drug treatment was supplemented with instillations into the rectum of the drug on sodium hyaluronate (0.8 mg of hyaluronic acid in 1 ml). The comparative assessment of the results of treatment took into account the severity of clinical, laboratory and endoscopic manifestations of the disease.Results. In patients of the main group, there was a significant reduction in the healing time of erosions and ulceration of the mucous membrane of the distal colon compared with patients in the control group (29.4 ± 5.7 days, respectively, versus 52.8 ± 6.2 days). Also, in patients of the main group, it was possible to achieve stable clinical and laboratory remission of the disease at an earlier time, restoration of patients’ ability to work, and improvement of their quality of life.Conclusion. The results obtained by us allow us to recommend the drug on sodium hyaluronate as an additional topical drug for the medical treatment of chronic diseases of the distal colon of various inflammatory genesis in outpatient settings.
Reference31 articles.
1. Белоусова ЕА, Шелыгин ЮА. Язвенный колит: клинические рекомендации по диагностике и консервативному лечению (адаптированный вариант в схемах и алгоритмах). М.: Рекламное агентство «Ре Медиа»; 2021. 48 с. Режим доступа: https://ibd-care.ru/wp-content/uploads/2022/02/kr-yaz_kolit-2021.pdf.
2. Bessissow T, Kron C, Marcus V, Lemieux C, Laneuville J, Afif W et al. Impact of Endoscopic and Histologic Activity on Disease Relapse in Ulcerative Colitis. Am J Gastroenterol. 2022;117(10):1632–1638. https://doi.org/10.14309/ajg.0000000000001912.
3. Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis. 2021;15(6):879–913. https://doi.org/10.1093/ecco-jcc/jjab052.
4. Hindryckx P, Jairath V, D’Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13(11):654–664. https://doi.org/10.1038/nrgastro.2016.116.
5. Khalif IL, Nanaeva BA, Golovenko AO, Golovenko OV. Long-term results of medical treatment of patients with a severe attack of ulcerative colitis. Terapevticheskii Arkhiv. 2015;87(2):34–38. (In Russ.) https://doi.org/10.17116/terarkh201587234-38.